[go: up one dir, main page]

NO960619L - Antipsychotic method - Google Patents

Antipsychotic method

Info

Publication number
NO960619L
NO960619L NO960619A NO960619A NO960619L NO 960619 L NO960619 L NO 960619L NO 960619 A NO960619 A NO 960619A NO 960619 A NO960619 A NO 960619A NO 960619 L NO960619 L NO 960619L
Authority
NO
Norway
Prior art keywords
mammal
antipsychotic method
antipsychotic
schizophrenia
sulphur
Prior art date
Application number
NO960619A
Other languages
Norwegian (no)
Other versions
NO312706B1 (en
NO960619D0 (en
Inventor
Franklin Porter Bymaster
Harlan E Shannon
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO960619D0 publication Critical patent/NO960619D0/en
Publication of NO960619L publication Critical patent/NO960619L/en
Publication of NO312706B1 publication Critical patent/NO312706B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

The present invention relates to a novel method for treating a mammal suffering from or susceptible to schizophrenia and schizophreniform diseases comprising administering to said mammal an effective amount of a compound of formula (I), wherein Z<1> is oxygen or sulphur.
NO19960619A 1993-08-19 1996-02-16 Use of Thiadiazole Compounds for the Preparation of Pharmaceutical Preparations for the Treatment of Schizophrenia and Schizophreniform Diseases NO312706B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10930093A 1993-08-19 1993-08-19
PCT/DK1994/000305 WO1995005174A1 (en) 1993-08-19 1994-08-15 Antipsychotic method

Publications (3)

Publication Number Publication Date
NO960619D0 NO960619D0 (en) 1996-02-16
NO960619L true NO960619L (en) 1996-04-18
NO312706B1 NO312706B1 (en) 2002-06-24

Family

ID=22326932

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19960619A NO312706B1 (en) 1993-08-19 1996-02-16 Use of Thiadiazole Compounds for the Preparation of Pharmaceutical Preparations for the Treatment of Schizophrenia and Schizophreniform Diseases

Country Status (23)

Country Link
EP (1) EP0734259B1 (en)
JP (1) JP3126736B2 (en)
KR (1) KR100360575B1 (en)
CN (1) CN1087936C (en)
AT (1) ATE218864T1 (en)
AU (1) AU701292B2 (en)
CA (1) CA2169839C (en)
CZ (1) CZ285030B6 (en)
DE (1) DE69430816T2 (en)
DK (1) DK0734259T3 (en)
ES (1) ES2177581T3 (en)
FI (2) FI960747A7 (en)
HU (1) HU221729B1 (en)
IL (1) IL110708A (en)
NO (1) NO312706B1 (en)
NZ (2) NZ336597A (en)
PT (1) PT734259E (en)
RU (1) RU2191580C2 (en)
SG (1) SG55071A1 (en)
TW (1) TW442284B (en)
UA (1) UA63876C2 (en)
WO (1) WO1995005174A1 (en)
ZA (1) ZA946324B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821371A (en) * 1994-10-24 1998-10-13 Eli Lilly And Comany Heterocyclic compounds and their preparation and use
US5605908A (en) * 1994-10-24 1997-02-25 Eli Lilly And Company Heterocyclic compounds and their use
US5998404A (en) 1994-10-24 1999-12-07 Eli Lilly And Company Heterocyclic compounds and their use
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
IL115811A0 (en) * 1994-10-31 1996-01-19 Lilly Co Eli Method for treating anxiety
US5726193A (en) * 1994-10-31 1998-03-10 Eli Lilly And Company Method for treating anxiety
US5488056A (en) * 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety
US5565475A (en) * 1994-11-08 1996-10-15 Muhlhauser; Mark A. Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
US5763457A (en) * 1995-11-13 1998-06-09 Eli Lilly And Company Method for treating anxiety
US5852037A (en) * 1995-11-13 1998-12-22 Eli Lilly And Company Method for treating anxiety
US6117890A (en) * 1996-08-01 2000-09-12 Eli Lilly And Company Method for treating bipolar disorder
EP0821956A1 (en) * 1996-08-01 1998-02-04 Eli Lilly And Company Method for treating disruptive behavior disorders
US6090829A (en) * 1996-08-01 2000-07-18 Eli Lilly And Company Method for treating excessive aggression
EP0821958A3 (en) * 1996-08-01 1998-07-08 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating excessive aggression
US6043258A (en) * 1996-08-01 2000-03-28 Eli Lilly And Company Method for treating disruptive behavior disorders with xanomeline
EP0821957A3 (en) * 1996-08-01 1998-04-22 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse
EP0821954A1 (en) * 1996-08-01 1998-02-04 Eli Lilly And Company Method for treating mental retardation
ES2171838T3 (en) * 1996-08-01 2002-09-16 Lilly Co Eli USE OF 3- (4-HEXILOXI-1,2,5-TIADIAZOL-3-IL) -1,2,5,6-TETRAHIDRO-1-METHYLIPIRIDINE (XANOMELINE) FOR THE TREATMENT OF BIPOLAR DISORDER.
EP0821959A3 (en) * 1996-08-01 1998-09-16 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine for treating nicotine withdrawal
ES2227836T3 (en) 1997-05-29 2005-04-01 H. Lundbeck A/S TREATMENT OF SCHIZOPHRENIA AND PSYCHOSIS.
US6034108A (en) * 1997-07-28 2000-03-07 Eli Lilly And Company Method for treating mental retardation
US20110020423A1 (en) 2009-07-22 2011-01-27 Puretech Ventures Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
AU2019346626B2 (en) 2018-09-28 2022-06-02 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
WO2021097427A1 (en) 2019-11-15 2021-05-20 Karuna Therapeutics, Inc. Xanomeline derivatives and methods for treating neurological disorders
CN115974863B (en) * 2021-10-14 2024-12-31 南京迈诺威医药科技有限公司 Malic acid salt of Xanomeline derivative, crystal form A, and preparation method and use thereof
CN119161338B (en) * 2024-11-25 2025-06-17 嘉兴安帝康生物科技有限公司 Tetrahydropyridine derivatives as muscarinic receptor agonists and their use in medicine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225999A (en) * 1987-09-10 1992-04-28 Merck Sharp & Dohme Azacyclic- or azabicyclic-substituted thiadiazole derivatives and pharmaceutical compositions
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
DK198490D0 (en) * 1990-08-21 1990-08-21 Novo Nordisk As HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND USE
DK198390D0 (en) * 1990-08-21 1990-08-21 Novo Nordisk As HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND USE

Also Published As

Publication number Publication date
AU7490294A (en) 1995-03-14
DE69430816D1 (en) 2002-07-18
ES2177581T3 (en) 2002-12-16
CZ42696A3 (en) 1996-11-13
HUT75111A (en) 1997-04-28
IL110708A0 (en) 1994-11-11
CA2169839A1 (en) 1995-02-23
TW442284B (en) 2001-06-23
KR100360575B1 (en) 2003-03-10
JP3126736B2 (en) 2001-01-22
SG55071A1 (en) 1998-12-21
ATE218864T1 (en) 2002-06-15
UA63876C2 (en) 2004-02-16
FI20050461L (en) 2005-04-29
NO312706B1 (en) 2002-06-24
AU701292B2 (en) 1999-01-21
WO1995005174A1 (en) 1995-02-23
DK0734259T3 (en) 2002-09-30
NO960619D0 (en) 1996-02-16
IL110708A (en) 1998-12-06
FI960747L (en) 1996-04-17
HU221729B1 (en) 2002-12-28
DE69430816T2 (en) 2002-12-19
JPH09501658A (en) 1997-02-18
NZ271311A (en) 1999-09-29
ZA946324B (en) 1996-02-19
CN1087936C (en) 2002-07-24
PT734259E (en) 2002-11-29
EP0734259B1 (en) 2002-06-12
FI20050461A7 (en) 2005-04-29
HU9600364D0 (en) 1996-04-29
CZ285030B6 (en) 1999-05-12
RU2191580C2 (en) 2002-10-27
KR960703592A (en) 1996-08-31
FI960747A7 (en) 1996-04-17
EP0734259A1 (en) 1996-10-02
CA2169839C (en) 2002-06-11
CN1133008A (en) 1996-10-09
FI960747A0 (en) 1996-02-19
NZ336597A (en) 2001-02-23

Similar Documents

Publication Publication Date Title
DK0734259T3 (en) Antipsychotic method
EP0604641A4 (en) Composition containing amine and amine-related derivatives of benzoic acid and uses therefor including treating inflammatory diseases.
EP0613883A4 (en) Hydroxamic acid derivative.
DE69902634D1 (en) SUBSTITUTED AMINOPHENYLISOXAZOLINE DERIVATIVES USED AS ANTIMICROBIAL AGENTS
IL99525A0 (en) Fused ring analogs of nitrogen containing nonaromatic heterocycles
FI960748A0 (en) Antipsychotic procedure
TW232013B (en)
ES2157887T3 (en) HETEROCICLICAL COMPOUNDS CONTAINING SULFUR.
BR9611472A (en) Sulfur-containing di-tert-butylphenol compounds useful as anti-inflammatory agents
ATE169217T1 (en) USE OF FURANONE DERIVATIVES TO PREVENT OR TREAT AUTOIMMUNE DISEASES
GR852867B (en)
DE69019920D1 (en) Benzocycloalkylaminopyridinamines and related compounds, processes for their preparation, intermediates and their use as medicines.
NO20003481L (en) Procedure for the treatment of COPD
DE68911237D1 (en) Nonionic triiodine compounds and contrast agents containing them.
ES2123728T3 (en) DERIVATIVES OF PYRROLLO-PYRAZINE ACTIVITY 5-HT3.
ATE118209T1 (en) PYRIDINE-3-PERCARBOXYLIC ACID MONOPERSULFATE.
ATE50762T1 (en) 3-(INDAN-5-YLOXY (OR THIO)&gt;CYCLOPENTANCARBONS|URE ANALOGUESAND TREATMENT AGENT INCLUDING THEM.
MX9709275A (en) Use of sulfamic acid derivatives, acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels.

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO, NO

MM1K Lapsed by not paying the annual fees